Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years

Haim Werner, Ernst A. Chantelau

Research output: Contribution to journalReview articlepeer-review

Abstract

In order to provide comprehensive information on the differences in bioactivity between human insulin and insulin analogues, published in vitro comparisons of human insulin and the rapid acting analogues insulin lispro (Humalog®), insulin aspart (NovoRapid®), insulin glulisine (Apidra®), and the slow acting analogues insulin glargine (Lantus®), and insulin detemir (Levemir®) were gathered from the past 20 years (except for receptor binding studies). A total of 50 reports were retrieved, with great heterogeneity among study methodology. However, various differences in bioactivity compared to human insulin were obvious (e.g. differences in effects on metabolism, mitogenesis, apoptosis, intracellular signalling, thrombocyte function, protein degradation). Whether or not these differences have clinical bearings (and among which patient populations) remains to be determined.

Original languageEnglish
Article number13
JournalDiabetology and Metabolic Syndrome
Volume3
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Dive into the research topics of 'Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years'. Together they form a unique fingerprint.

Cite this